Tower Research Capital LLC (Trc) Macrogenics Inc Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Macrogenics Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 16,763 shares of MGNX stock, worth $25,815. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,763
Previous 20,679
18.94%
Holding current value
$25,815
Previous $25,000
12.0%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding MGNX
# of Institutions
111Shares Held
50MCall Options Held
65.5KPut Options Held
93.9K-
Bellevue Group Ag Kuesnacht, V89.92MShares$15.3 Million0.36% of portfolio
-
Armistice Capital, LLC New York, NY5.96MShares$9.18 Million0.16% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$8.32 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$6.51 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.18MShares$4.89 Million0.23% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $94.6M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...